
|Articles|October 10, 2011
Supplements and Featured Publications
- The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson's Disea
- Volume 17
- Issue 12 Suppl
The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson's Disease
Advertisement
After reading "The Case for Early Initiation of Monotherapies and Delayed Dopaminergic Therapy in Parkinson’s Disease,” participants must complete the online evaluation form and achieve a passing score of 70% or higher on the online posttest. Upon submission of the completed evaluation and posttest, participants may print their statement of credit.
Articles in this issue
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves Nerandomilast for Idiopathic Pulmonary Fibrosis
2
Pulling Back Funding for Research Could Leave HIV Treatment in Worse State: Patrick Sullivan, DVM, PhD
3
Value-Based Care Interventions and Management of CKD Progression
4
FDA Approves Cemiplimab as First, Only Adjuvant Immunotherapy for High-Risk CSCC
5